menu
    • menu
    [{"orgOrder":0,"company":"Innate Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Lacutamab","moa":"Killer cell immunoglobulin-like receptor 3DL2","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Lacutamab","moa":"Killer cell immunoglobulin-like receptor 3DL2","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lymphoma Academic Research Organisation","sponsor":"Innate Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lacutamab","moa":"Killer cell immunoglobulin-like receptor 3DL2","graph1":"Oncology","graph2":"Phase II","graph3":"Lymphoma Academic Research Organisation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lymphoma Academic Research Organisation \/ Innate Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Lymphoma Academic Research Organisation \/ Innate Pharma"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lacutamab","moa":"Killer cell immunoglobulin-like receptor 3DL2","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innate Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lacutamab","moa":"Killer cell immunoglobulin-like receptor 3DL2","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innate Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lacutamab","moa":"Killer cell immunoglobulin-like receptor 3DL2","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innate Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lacutamab","moa":"||Killer cell immunoglobulin-like receptor 3DL2","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innate Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Lacutamab","moa":"Killer cell immunoglobulin-like receptor 3DL2","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innate Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Lacutamab","moa":"Killer cell immunoglobulin-like receptor 3DL2","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innate Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lacutamab","moa":"||Killer cell immunoglobulin-like receptor 3DL2","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innate Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lacutamab","moa":"||Killer cell immunoglobulin-like receptor 3DL2","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lacutamab","moa":"||Killer cell immunoglobulin-like receptor 3DL2","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lacutamab","moa":"||Killer cell immunoglobulin-like receptor 3DL2","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lacutamab","moa":"||Killer cell immunoglobulin-like receptor 3DL2","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lacutamab","moa":"||Killer cell immunoglobulin-like receptor 3DL2","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Lacutamab

    Menu

    Lacutamab

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Innate Pharma

                            France arrow
                            CTAD25
                            Not Confirmed

                            Innate Pharma

                            France arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lacutamab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Innate Wins FDA Breakthrough Status for Lacutamab in Sézary Syndrome

                            Details : IPH4102 (lacutamab) is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, being evaluated for cutaneous T-cell lymphoma and peripheral T cell lymphoma.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            February 17, 2025

                            Lead Product(s) : Lacutamab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Innate Pharma

                            France arrow
                            CTAD25
                            Not Confirmed

                            Innate Pharma

                            France arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lacutamab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program

                            Details : IPH4102 (lacutamab) is an anti-KIR3DL2 humanized antibody in phase 2 trials for cutaneous T-cell lymphoma and peripheral T-cell lymphoma treatment.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            January 03, 2024

                            Lead Product(s) : Lacutamab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Innate Pharma

                            France arrow
                            CTAD25
                            Not Confirmed

                            Innate Pharma

                            France arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lacutamab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Innate Pharma Provides Update on Lacutamab Clinical Program

                            Details : IPH4102 (lacutamab) is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody that is currently in clinical trials for treatment of cutaneous T-cell lymphoma (CTCL), an orphan disease, and peripheral T cell lymphoma (PTCL).

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            October 05, 2023

                            Lead Product(s) : Lacutamab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Innate Pharma

                            France arrow
                            CTAD25
                            Not Confirmed

                            Innate Pharma

                            France arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lacutamab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab i...

                            Details : Lacutamab (IPH4102) is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody that is currently in clinical trials for treatment of cutaneous T-cell lymphoma (CTCL), an orphan disease, and peripheral T cell lymphoma (PTCL).

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            December 10, 2022

                            Lead Product(s) : Lacutamab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Innate Pharma

                            France arrow
                            CTAD25
                            Not Confirmed

                            Innate Pharma

                            France arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lacutamab,Gemcitabine,Oxaliplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Innate Pharma to Present Lacutamab PTCL Phase 1b Design and ANKET™ Platform at ESMO 2022

                            Details : Lacutamab (IPH4102) is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody that is currently in clinical trials for treatment of cutaneous T-cell lymphoma (CTCL), an orphan disease, and peripheral T cell lymphoma (PTCL).

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            September 05, 2022

                            Lead Product(s) : Lacutamab,Gemcitabine,Oxaliplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Innate Pharma

                            France arrow
                            CTAD25
                            Not Confirmed

                            Innate Pharma

                            France arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lacutamab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express ...

                            Details : Lacutamab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, T-Cell, Peripheral.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            April 11, 2022

                            Lead Product(s) : Lacutamab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Lymphoma Academic Research Organisation

                            Country arrow
                            CTAD25
                            Not Confirmed

                            Lymphoma Academic Research Organisation

                            Country arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lacutamab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Innate Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Lacutamab in Peripheral T-cell Lymphoma

                            Details : Lacutamab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma, T-Cell, Peripheral.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            August 02, 2021

                            Lead Product(s) : Lacutamab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Innate Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Innate Pharma

                            France arrow
                            CTAD25
                            Not Confirmed

                            Innate Pharma

                            France arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lacutamab,Gemcitabine,Oxaliplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Innate Pharma Presents Preliminary Data from TELLOMAK Trial Showing Clinical Response for Lacutamab in Mycosis...

                            Details : Lacutamab demonstrated clinical responses in patients with MF that express KIR3DL2 (cohort 2), reaching the pre-determined threshold to advance to stage 2.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            June 22, 2021

                            Lead Product(s) : Lacutamab,Gemcitabine,Oxaliplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Innate Pharma

                            France arrow
                            CTAD25
                            Not Confirmed

                            Innate Pharma

                            France arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lacutamab,Gemcitabine,Oxaliplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            New Lacutamab Data from TELLOMAK Trial to be Showcased in Oral Presentation at Upcoming 16th International Con...

                            Details : Lacutamab (IPH4102) is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is currently in clinical trials for treatment of cutaneous T-cell lymphoma (CTCL), an orphan disease.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            June 09, 2021

                            Lead Product(s) : Lacutamab,Gemcitabine,Oxaliplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Innate Pharma

                            France arrow
                            CTAD25
                            Not Confirmed

                            Innate Pharma

                            France arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lacutamab,Gemcitabine,Oxaliplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Innate Pharma Advances Lacutamab Clinical Development Program

                            Details : Company to initiate two new clinical trials to investigate lacutamab in peripheral T-cell lymphoma, including Phase 2 combination study with leading global lymphoma research network, LYSA.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            February 09, 2021

                            Lead Product(s) : Lacutamab,Gemcitabine,Oxaliplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth